undamentalytics Newsletter
Sign in

Aardvark Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Aardvark Therapeutics, Inc. had total assets of $117m, total liabilities of $10.5m and shareholders' equity of $107m. It held $47.1m in cash against $0 of debt: net cash of $47.1m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2025Dec 2025LTMJun 2026
Cash and equivalents4774
Total current assets11281
Total assets11781
Accounts payable22
Total current liabilities116
Total debt00
Total liabilities117
Shareholders' equity10775
Net debt (negative = net cash)−47−74
Shares outstanding22m22m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aardvark Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aardvark Therapeutics, Inc.